Alkem Laboratories Ltd
NSE:ALKEM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
4 521.15
6 366.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALKEM stock under the Base Case scenario is 4 037.49 INR. Compared to the current market price of 5 583.35 INR, Alkem Laboratories Ltd is Overvalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Alkem Laboratories Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALKEM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Alkem Laboratories Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Alkem Laboratories Ltd. is a prominent player in the pharmaceutical industry, rooted in its commitment to research, development, and manufacturing of high-quality generic medications. Founded in 1973 and headquartered in Mumbai, India, Alkem has successfully carved out a significant market share in both domestic and international markets. With a diverse product portfolio encompassing over 700 generics across various therapeutic categories, the company's innovative approach and stringent adherence to regulatory compliance have earned it a robust reputation. Alkem's strategic focus on expanding its presence in key global markets, particularly the United States, positions it well to capitalize...
Alkem Laboratories Ltd. is a prominent player in the pharmaceutical industry, rooted in its commitment to research, development, and manufacturing of high-quality generic medications. Founded in 1973 and headquartered in Mumbai, India, Alkem has successfully carved out a significant market share in both domestic and international markets. With a diverse product portfolio encompassing over 700 generics across various therapeutic categories, the company's innovative approach and stringent adherence to regulatory compliance have earned it a robust reputation. Alkem's strategic focus on expanding its presence in key global markets, particularly the United States, positions it well to capitalize on the growing demand for affordable healthcare solutions.
As investors look for opportunities in the pharmaceutical sector, Alkem Laboratories stands out not just for its ambitious growth trajectory, but also for its proven track record of delivering consistent financial performance. The company's recent investments in state-of-the-art facilities and research initiatives underscore its dedication to innovation and efficiency. Furthermore, with a robust pipeline of products in various stages of development, Alkem is well-equipped to navigate the dynamic regulatory landscape and competitive pressures in the industry. For investors, the blend of Alkem's established market position, commitment to quality, and proactive expansion strategy signals a compelling opportunity backed by solid fundamentals.
Alkem Laboratories Ltd. is a prominent Indian pharmaceutical company known for its diverse range of pharmaceutical products and services. The core business segments of Alkem Laboratories can be categorized as follows:
-
Pharmaceuticals:
-
Branded Formulations: This segment includes a wide variety of prescription medications across multiple therapeutic areas, such as cardiology, gastroenterology, anti-infectives, pain management, and more. The company focuses on developing and marketing high-quality branded products in domestic and international markets.
-
Generic Formulations: Alkem manufactures and sells generic medications that are bioequivalent to branded drugs. This segment is crucial in meeting patient needs while also being cost-effective.
-
-
Biotechnology:
- Alkem has a growing presence in the biotechnology space, focusing on the development and commercialization of biologics, which include therapeutic proteins and monoclonal antibodies. This area of their business targets complex diseases, including cancer and autoimmune disorders.
-
Active Pharmaceutical Ingredients (APIs):
- Alkem produces a range of APIs, which are the active components used in pharmaceutical formulations. The API segment is essential for both internal use in their own formulations and for supplying to third-party manufacturers.
-
Over-the-Counter (OTC) Products:
- This segment includes consumer health products that are available without a prescription. Alkem markets a variety of OTC products, focusing on categories like pain relief, cold and flu remedies, and dietary supplements.
-
International Operations:
- Alkem has a significant presence in various international markets, particularly in the United States, where it sells branded and generic products. This segment is critical for revenue diversification and growth, given the robust demand for affordable healthcare solutions in global markets.
-
Nutraceuticals:
- Alkem is also engaged in the nutraceutical space, which includes functional foods and dietary supplements aimed at promoting health and wellness. This is an area of increasing interest as consumers become more health-conscious.
By leveraging these core business segments, Alkem Laboratories Ltd. aims to capitalize on growth opportunities in both domestic and international markets while addressing diverse healthcare needs. Their strategic focus on research and development, quality assurance, and regulatory compliance supports their competitive position in the pharmaceutical industry.
Alkem Laboratories Ltd, being a prominent player in the pharmaceuticals sector, holds several unique competitive advantages that can set it apart from its rivals. Here are some key aspects:
-
Strong Brand Portfolio: Alkem has a diverse and robust portfolio of established brands across various therapeutic segments. This brand recognition fosters customer loyalty and can lead to consistent demand for its products.
-
Extensive Distribution Network: The company has a wide and efficient distribution network in India and abroad, allowing it to reach a large number of healthcare professionals and patients. This accessibility can be a significant advantage in market penetration.
-
Focus on Research and Development: Alkem invests heavily in R&D to develop innovative products and improve existing formulations. This focus not only enhances product efficacy but also helps in filing for patents, which can provide a competitive edge through exclusivity.
-
Cost Efficiency: With efficient manufacturing processes and economies of scale, Alkem can maintain lower production costs. This allows them to offer competitive pricing while also sustaining profitability.
-
Regulatory Approvals and Quality Compliance: Alkem has a strong track record in obtaining regulatory approvals for its products in various international markets. Compliance with high-quality standards (like GMP) enhances its credibility and reduces the risk of product recalls or regulatory issues.
-
Strong Financial Position: The company has shown robust growth and profitability, which provides the leverage for investment in growth opportunities, whether through acquisitions, R&D, or expanding its product range.
-
Strategic Acquisitions: Alkem has pursued strategic acquisitions to bolster its product portfolio and enhance market presence, especially in niche segments that can yield high margins.
-
Global Presence: Besides a strong domestic market, Alkem has a growing international footprint, especially in the U.S. and other regulated markets. This diversification reduces dependency on any single market.
-
Extensive Product Pipeline: A well-defined product pipeline prepared for various drug formulations allows Alkem to maintain a competitive edge by bringing new products to market regularly.
-
Vertical Integration: Alkem manages multiple aspects of its supply chain, from production to marketing. This vertical integration helps in controlling costs and ensuring product quality.
By leveraging these advantages, Alkem Laboratories Ltd can reinforce its market position and successfully compete against rivals in the pharmaceutical industry.
Alkem Laboratories Ltd., like many companies in the pharmaceutical sector, faces a variety of risks and challenges in the near future. Here are some key areas of concern:
-
Regulatory Compliance: The pharmaceutical industry is heavily regulated. Changes in regulations or stricter enforcement could impact Alkem’s operations, especially in areas related to drug approvals, manufacturing practices, and marketing.
-
Pricing Pressure: There is ongoing pressure on drug prices from both public and private payers. This pressure could impact Alkem’s margins and profitability, particularly for generic pharmaceuticals, which make up a significant portion of their portfolio.
-
Intellectual Property Risks: Patent expirations and the threat of generic competition can erode the market for branded drugs. Alkem must continually invest in research and development to create new products and protect its intellectual property.
-
Supply Chain Vulnerabilities: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. Disruptions due to geopolitical tensions, natural disasters, or other logistical issues could affect the availability of raw materials and the distribution of products.
-
Market Competition: The pharmaceutical industry is highly competitive. Alkem faces competition from both established players and emerging biotech firms. Maintaining market share will require continuous innovation and effective marketing strategies.
-
Litigation Risks: The company may face lawsuits related to product liability, patent disputes, or regulatory compliance. Legal expenses can be significant, and adverse outcomes could impact financial performance and reputation.
-
Emerging Market Fluctuations: As Alkem expands into emerging markets, it will need to navigate economic volatility, currency fluctuations, and varying regulatory landscapes, all of which can pose risks to growth and stability.
-
R&D Challenges: Pharmaceutical research and development is notoriously unpredictable. The failure of key drugs in clinical trials or delays in bringing new products to market can adversely affect Alkem’s competitive positioning and financial performance.
-
Technological Advancements: The rapid pace of technological change in pharmacology, including advances in biologics and personalized medicine, means that Alkem must continuously adapt its strategies and invest in new technologies.
-
Global Health Crises: Future pandemics or health crises can disrupt operations, change consumer behavior, and lead to uncertainty in the market. This includes potential impacts on both supply chains and sales.
Companies like Alkem Laboratories can mitigate some of these risks by diversifying their product portfolios, investing in innovative R&D, maintaining strong regulatory affairs teams, and adapting to changing market conditions quickly. However, the inherent uncertainties in the pharmaceutical sector will always present challenges.
Revenue & Expenses Breakdown
Alkem Laboratories Ltd
Balance Sheet Decomposition
Alkem Laboratories Ltd
Current Assets | 104.1B |
Cash & Short-Term Investments | 38.2B |
Receivables | 30.6B |
Other Current Assets | 35.3B |
Non-Current Assets | 51.6B |
Long-Term Investments | 4.1B |
PP&E | 25.6B |
Intangibles | 4.7B |
Other Non-Current Assets | 17.3B |
Current Liabilities | 39.9B |
Accounts Payable | 17.5B |
Accrued Liabilities | 6.1B |
Short-Term Debt | 11.7B |
Other Current Liabilities | 4.6B |
Non-Current Liabilities | 12.7B |
Long-Term Debt | 2.3B |
Other Non-Current Liabilities | 10.4B |
Earnings Waterfall
Alkem Laboratories Ltd
Revenue
|
127.3B
INR
|
Cost of Revenue
|
-48.1B
INR
|
Gross Profit
|
79.2B
INR
|
Operating Expenses
|
-57.6B
INR
|
Operating Income
|
21.6B
INR
|
Other Expenses
|
-1.1B
INR
|
Net Income
|
20.5B
INR
|
Free Cash Flow Analysis
Alkem Laboratories Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY '25, Alkem Laboratories reported 0.6% revenue growth with significant EBITDA improvements, reaching a margin of 21.1%, up from 17.7% last year. Net profit surged 36% year-over-year to INR 12,338 million. The company expects mid-single-digit revenue growth for the year, primarily impacted by challenges in the U.S. market, where they predict a 15% decline due to pricing and volume issues. In contrast, domestic growth is projected at 8-9%. Alkem is focusing on high-margin segments and aims for a 100 basis point improvement in EBITDA margin, targeting 18.5-19% by year-end.
What is Earnings Call?
ALKEM Profitability Score
Profitability Due Diligence
Alkem Laboratories Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Alkem Laboratories Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ALKEM Solvency Score
Solvency Due Diligence
Alkem Laboratories Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Score
Alkem Laboratories Ltd's solvency score is 90/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALKEM Price Targets Summary
Alkem Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for ALKEM is 5 793.77 INR with a low forecast of 4 373.3 INR and a high forecast of 7 586.25 INR.
Dividends
Current shareholder yield for ALKEM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALKEM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,966 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm operates through pharmaceuticals segment. The firm produces generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and approximately 50 countries internationally. The firm offers its products across various therapeutic areas, such as anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, Rheumatology, central nervous system (CNS), oncology, urology and gynecology. The firm offers its products under various brands, including Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Gemcal, Taxim, Sumo, Maxvoid Plus, Tamsukem Plus and Neurokem NT. The firm has approximately 20 manufacturing facilities, of which 18 manufacturing facilities are located in India and two in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one ALKEM stock under the Base Case scenario is 4 037.49 INR.
Compared to the current market price of 5 583.35 INR, Alkem Laboratories Ltd is Overvalued by 28%.